Cookson Peirce & Co. Inc. Takes $113,000 Position in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX)

Cookson Peirce & Co. Inc. acquired a new stake in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 250,000 shares of the company’s stock, valued at approximately $113,000. Cookson Peirce & Co. Inc. owned 0.11% of Lineage Cell Therapeutics at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the business. JPMorgan Chase & Co. raised its stake in shares of Lineage Cell Therapeutics by 39.8% in the fourth quarter. JPMorgan Chase & Co. now owns 946,399 shares of the company’s stock valued at $476,000 after purchasing an additional 269,237 shares in the last quarter. Wells Fargo & Company MN raised its stake in shares of Lineage Cell Therapeutics by 33.0% in the fourth quarter. Wells Fargo & Company MN now owns 94,894 shares of the company’s stock valued at $48,000 after purchasing an additional 23,527 shares in the last quarter. Renaissance Technologies LLC raised its stake in shares of Lineage Cell Therapeutics by 1,058.3% in the fourth quarter. Renaissance Technologies LLC now owns 2,283,072 shares of the company’s stock valued at $1,147,000 after purchasing an additional 2,085,972 shares in the last quarter. Barclays PLC raised its stake in shares of Lineage Cell Therapeutics by 10.8% in the fourth quarter. Barclays PLC now owns 234,069 shares of the company’s stock valued at $118,000 after purchasing an additional 22,769 shares in the last quarter. Finally, Comerica Bank raised its stake in shares of Lineage Cell Therapeutics by 220.0% in the fourth quarter. Comerica Bank now owns 800,000 shares of the company’s stock valued at $402,000 after purchasing an additional 550,000 shares in the last quarter. 62.47% of the stock is owned by institutional investors.

Lineage Cell Therapeutics Price Performance

Lineage Cell Therapeutics stock opened at $1.20 on Friday. The stock has a fifty day moving average price of $0.98 and a two-hundred day moving average price of $0.68. Lineage Cell Therapeutics, Inc. has a 52-week low of $0.37 and a 52-week high of $1.31. The firm has a market capitalization of $274.03 million, a P/E ratio of -6.67 and a beta of 1.66.

Analyst Ratings Changes

A number of research analysts recently commented on the company. D. Boral Capital restated a “buy” rating and issued a $2.00 target price on shares of Lineage Cell Therapeutics in a research note on Thursday. HC Wainwright reiterated a “buy” rating and set a $9.00 price objective on shares of Lineage Cell Therapeutics in a research note on Monday, June 23rd. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $4.20.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.